Correspondence | Published:

Genome editing

Broad Institute keeps CRISPR tools open

Nature volume 534, page 37 (02 June 2016) | Download Citation

As chief communications officer at the Broad Institute of MIT and Harvard, I wish to clarify that the institute makes patent rights for CRISPR–Cas9 genome-editing technologies available globally across academia and industry (see J. Sherkow Nature 532, 172–173; 2016).

For academic research, the patent rights are freely available and we openly share CRISPR reagents through the non-profit repository Addgene. So far, Addgene has processed more than 30,000 requests for these reagents.

For commercial research, we designed a non-exclusive licensing model. For commercial products, we also follow a non-exclusive model — except for human therapeutics, for which we use an 'inclusive innovation model'. This is because companies often need exclusivity to justify investing in expensive clinical trials.

The CRISPR–Cas9 licensing agreement with our primary licensee, Editas, stipulates that, for target genes not being pursued by Editas, we (Broad, Harvard and MIT) will make the licences available to other parties to develop new medicines. This helps to ensure that no promising target genes will be neglected.

Author information


  1. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

    • Lee McGuire


  1. Search for Lee McGuire in:

Corresponding author

Correspondence to Lee McGuire.

About this article

Publication history




By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing